Back to the Xenexus Pharmaceutical Home Page

Xenexus Pharmaceuticals Xenexus Pharmaceuticals Xenexus Pharmaceuticals Xenexus Pharmaceuticals

Xenexus Pharmaceuticals, drugs, treatment, neurological disorders, alzheimer's, parkinson's, multiple sclerosis, MS


Programs

Xenexus is developing its lead compound XEN-101 for the treatment of gout. XEN-101 is an orally active small molecule with an excellent safety profile and a unique mechanism of action.

XEN-102 is a new orally active drug for the treatment of multiple sclerosis.

XEN-103 is a new orally active drug for the treatment of rheumatoid arthritis (under development).

XEN-104 is a topical treatment for wound healing and skin repair (under development).






© 2011 Xenexus Pharmaceuticals Pty Ltd Home  /  Company  /  Programs  /  Contact by Echidna Web Design. Click here to visit.